Bio-rad Laboratories Stock News

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market. The report gives a guide to the flow cytometry market which will be shaping and changing our lives over the next ten years and beyond, including the market''s response to the challenge of the global pandemic Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market.

https://www.investing.com/news/stock-market-news/biorad-laboratories-up-7-after-investor-day-2772756

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

The recent market rout offers an opportune entry point to these seven robust stocks. These are good stocks to buy at their bottom now.

For the past half dozen years, investors couldn't care less about a company's balance sheet.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv